Modality
Peptide
MOA
BETi
Target
JAK2
Pathway
Angiogenesis
RB
Development Pipeline
Preclinical
~Jun 2015
→ ~Sep 2016
Phase 1
~Dec 2016
→ ~Mar 2018
Phase 2
~Jun 2018
→ ~Sep 2019
Phase 3
~Dec 2019
→ ~Mar 2021
NDA/BLA
Jun 2021
→ Jan 2029
NDA/BLACurrent
NCT08180470
494 pts·RB
2021-06→2029-01·Terminated
NCT04706372
2,162 pts·RB
2025-01→2026-05·Not yet recruiting
2,656 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-05-242mo awayPh3 Readout· RB
2029-01-222.8y awayPh3 Readout· RB
Trial Timeline
Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029
NDA/BLA
Termina…
NDA/BLA
Not yet…
Catalysts
Ph3 Readout
2026-05-24 · 2mo away
RB
Ph3 Readout
2029-01-22 · 2.8y away
RB
TerminatedNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08180470 | NDA/BLA | RB | Terminated | 494 | Mayo |
| NCT04706372 | NDA/BLA | RB | Not yet recr... | 2162 | Biomarker |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-179 | Johnson & Johnson | Approved | KRASG12C | |
| LLY-1592 | Eli Lilly | NDA/BLA | FGFR | |
| Sovarapivir | AbbVie | Phase 2/3 | IL-13 | |
| BAY-8733 | Bayer | Preclinical | AuroraA | |
| BII-1564 | Biogen | Phase 2 | PSMA | |
| Sovanaritide | Argenx | Phase 3 | TNFα | |
| GMA-5010 | Genmab | Phase 3 | JAK2 | |
| 369-8021 | Hansoh Pharma | Approved | BTK | |
| Teravorutinib | Illumina | Phase 2 | JAK2 | |
| COR-9456 | Corcept | Preclinical | TIGIT |